Nathan K. VanLandingham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathan K. VanLandingham has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer R. Grandis
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA, USA
8 shared publications - Daniel E. Johnson
Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA
7 shared publications - Mi-Ok Kim
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
6 shared publications - Jacqueline P. Nguyen
Department of Otolaryngology–Head and Neck Surgery, University of California, San Francisco, California
5 shared publications - Kelly Blum
Department of Epidemiology and Biostatistics, University of California, San Francisco, California
5 shared publications - Liam C. Woerner
Department of Otolaryngology–Head and Neck Surgery, University of California, San Francisco, California
5 shared publications
Latest Publications
- 9 July 2026
- Published by SAGE Publications in Journal of Dental Research
Caspase-8 Mutation Promotes HNSCC Development and Resistance to Anti–PD-1
Heterozygous mutations of the gene encoding caspase-8 protease occur in 10% of human head and neck squamous cell carcinomas (HNSCCs). Cell line studies indicate that these mutations block apoptosis induced by death ligands. However, the in vivo role of caspase-8 mutations in the development of HNSCC and their impact on response to immune checkpoint blockade have not been determined. We generated mice with heterozygous, epithelium-specific knock-in of a representative, HNSCC-associated caspase-8 mutation (D305G). The impact of the caspase-8 mutation was assessed following treatment with the carcinogen 4-nitroquinoline-1-oxide (4NQO) in drinking water. Treatment of the D305G caspase-8 mutant mice with 4NQO resulted in a greater number of tongue tumors per mouse and a higher percentage of advanced-stage invasive carcinomas than was observed in 4NQO-treated mice with wild-type caspase-8, and tumors from the mutant mice were more resistant to anti–PD-1. We also engineered the murine oral cancer cell line MOC1 for heterozygous expression of caspase-8 mutations. Tumors generated from these engineered cells in syngeneic, immunocompetent mice demonstrated reduced responsiveness to anti–PD-1, relative to tumors with wild-type caspase-8. Further, the caspase-8 mutant tumors displayed reduced intratumoral and splenic CD8 + T cells and impaired recruitment of monocytes and dendritic cells during PD-1 blockade. Collectively, these findings demonstrate that caspase-8 mutation promotes carcinogen-induced HNSCC development and resistance to anti–PD-1. Investigation of caspase-8 mutations as potential biomarkers of poor response to immunotherapy in patients with HNSCC is warranted.
- 9 July 2026
- Published by SAGE Publications in Journal of Dental Research
Caspase-8 Mutation Promotes HNSCC Development and Resistance to Anti–PD-1
Heterozygous mutations of the gene encoding caspase-8 protease occur in 10% of human head and neck squamous cell carcinomas (HNSCCs). Cell line studies indicate that these mutations block apoptosis induced by death ligands. However, the in vivo role of caspase-8 mutations in the development of HNSCC and their impact on response to immune checkpoint blockade have not been determined. We generated mice with heterozygous, epithelium-specific knock-in of a representative, HNSCC-associated caspase-8 mutation (D305G). The impact of the caspase-8 mutation was assessed following treatment with the carcinogen 4-nitroquinoline-1-oxide (4NQO) in drinking water. Treatment of the D305G caspase-8 mutant mice with 4NQO resulted in a greater number of tongue tumors per mouse and a higher percentage of advanced-stage invasive carcinomas than was observed in 4NQO-treated mice with wild-type caspase-8, and tumors from the mutant mice were more resistant to anti–PD-1. We also engineered the murine oral cancer cell line MOC1 for heterozygous expression of caspase-8 mutations. Tumors generated from these engineered cells in syngeneic, immunocompetent mice demonstrated reduced responsiveness to anti–PD-1, relative to tumors with wild-type caspase-8. Further, the caspase-8 mutant tumors displayed reduced intratumoral and splenic CD8 + T cells and impaired recruitment of monocytes and dendritic cells during PD-1 blockade. Collectively, these findings demonstrate that caspase-8 mutation promotes carcinogen-induced HNSCC development and resistance to anti–PD-1. Investigation of caspase-8 mutations as potential biomarkers of poor response to immunotherapy in patients with HNSCC is warranted.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 2 shows Elevated COX2 protein expression in PTEN-deficient HNSCC cells. COX2 protein expression in PTEN knockout (PTEN KO) in Cal27 human and MOC22 murine cells was increased compared to parental cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 1 shows that loss of PTEN increases tumor growth. Tumor cells derived from MOC1 cells with PTEN loss or PIK3CA amplification (WT) or mutation (H1047R, E545K) were implanted subcutaneously in immunocompetent mice and tumor volumes were monitored for 19 days. Tumor volumes for MOC1 cells engineered for PIK3CA mutations H1047R (p=0.032) or E545K (p=0.0023) or PTEN KO (p=0.0079) were increased compared with tumors derived from parental control cells. The mean measurements and SD of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Supplemental Figure 3 shows that TPST-1495 enhances anti-PD1 anti-tumor activity. MOC1 cells engineered to express E545K PIK3CA mutation (2x106 cell/mouse) were implanted subcutaneously into flanks of immunocompetent C57BL/6 mice. Once tumors were palpable (about 100 mm3; approximately 10 days), mice were treated with vehicle (methylcellulose bi-daily and/or IgG), TPST-1495 (150 mg/kg, bi-daily), anti-PD1 (0.2 mg per mouse on days 1, 4, and 7 after palpable tumors were established), or the combination of TPST-1495 and anti-PD1 (n=5 per group). Concomitant administration of TPST-1495 and anti-PD1 showed an additive effect on tumor growth inhibition compared to anti-PD1 (p=0.001) alone. The mean measurements and SEM of each group are shown. * p<0.05 and ** p<0.01 determined by Dunnett’s method.
- 26 March 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 759, 151703
Neddylation as a target in PIK3CA-mutated head and neck cancer
- 26 March 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 759, 151703
Neddylation as a target in PIK3CA-mutated head and neck cancer
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 20 February 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 931-941
Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors
Increased PI3K signaling as a result of PIK3CA mutation or amplification or decreased expression of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is one of the most common alterations in head and neck squamous cell carcinoma (HNSCC). PTEN negatively regulates PI3K signaling and its downstream effectors including COX2. COX2 mediates the synthesis of prostaglandin E2 (PGE2) which contributes to immunosuppression in the tumor microenvironment. PGE2 also binds to one or more EP receptors (EP1–EP4) and promotes the growth of tumor cells via activation of EP2 and EP4. However, the role of PGE2 in PTEN-deficient HNSCC is incompletely understood. In this study, we assessed PGE2 signaling in PTEN-deficient HNSCC and evaluated the effect of aspirin or TPST-1495, a dual EP2/EP4 antagonist, on the growth of PTEN knockout and PIK3CA-altered HNSCC tumors in immunocompetent mice. Our results demonstrated that aspirin selectively inhibits the growth of PTEN knockout HNSCC tumors. TPST-1495 inhibited tumor growth and substantially increased the antitumor activity of the immune checkpoint inhibitor anti-PD1. To date, there are no FDA-approved therapies for PI3K pathway–altered HNSCC. Our findings suggest that NSAIDs demonstrate antitumor activity in PTEN-deficient or PI3K-altered tumors whereas EP2/EP4 targeting may augment FDA-approved anti-PD1 therapy in HNSCC.
- 15 November 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (22)
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Alpelisib selectively inhibits the p110α catalytic subunit of PI3Kα and is approved for treatment of breast cancers harboring canonical PIK3CA mutations. In head and neck squamous cell carcinoma (HNSCC), 63% of PIK3CA mutations occur at canonical hotspots. The oncogenic role of the remaining 37% of PIK3CA noncanonical mutations is incompletely understood. We report a patient with HNSCC with a noncanonical PIK3CA mutation (Q75E) who exhibited a durable (12 months) response to alpelisib in a phase II clinical trial. Characterization of all 32 noncanonical PIK3CA mutations found in HNSCC using several functional and phenotypic assays revealed that the majority (69%) were activating, including Q75E. The oncogenic impact of these mutations was validated in 4 cellular models, demonstrating that their activity was lineage independent. Further, alpelisib exhibited antitumor effects in a xenograft derived from a patient with HNSCC containing an activating noncanonical PIK3CA mutation. Structural analyses revealed plausible mechanisms for the functional phenotypes of the majority of the noncanonical PIK3CA mutations. Collectively, these findings highlight the importance of characterizing the function of noncanonical PIK3CA mutations and suggest that patients with HNSCC whose tumors harbor activating noncanonical PIK3CA mutations may benefit from treatment with PI3Kα inhibitors.
- 15 November 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (22)
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Alpelisib selectively inhibits the p110α catalytic subunit of PI3Kα and is approved for treatment of breast cancers harboring canonical PIK3CA mutations. In head and neck squamous cell carcinoma (HNSCC), 63% of PIK3CA mutations occur at canonical hotspots. The oncogenic role of the remaining 37% of PIK3CA noncanonical mutations is incompletely understood. We report a patient with HNSCC with a noncanonical PIK3CA mutation (Q75E) who exhibited a durable (12 months) response to alpelisib in a phase II clinical trial. Characterization of all 32 noncanonical PIK3CA mutations found in HNSCC using several functional and phenotypic assays revealed that the majority (69%) were activating, including Q75E. The oncogenic impact of these mutations was validated in 4 cellular models, demonstrating that their activity was lineage independent. Further, alpelisib exhibited antitumor effects in a xenograft derived from a patient with HNSCC containing an activating noncanonical PIK3CA mutation. Structural analyses revealed plausible mechanisms for the functional phenotypes of the majority of the noncanonical PIK3CA mutations. Collectively, these findings highlight the importance of characterizing the function of noncanonical PIK3CA mutations and suggest that patients with HNSCC whose tumors harbor activating noncanonical PIK3CA mutations may benefit from treatment with PI3Kα inhibitors.
- 1 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6563) , 49-+
A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV
- 1 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6563) , 49-+
A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity
Mapping protein interactions driving cancer: Cancer is a genetic disease, and much cancer research is focused on identifying carcinogenic mutations and determining how they relate to disease progression. Three papers demonstrate how mutations are processed through networks of protein interactions to promote cancer (see the Perspective by Cheng and Jackson). Swaney et al . focus on head and neck cancer and identify cancer-enriched interactions, demonstrating how point mutant–dependent interactions of PIK3CA, a kinase frequently mutated in human cancers, are predictive of drug response. Kim et al . focus on breast cancer and identify two proteins functionally connected to the tumor-suppressor gene BRCA1 and two proteins that regulate PIK3CA. Zheng et al . developed a statistical model that identifies protein networks that are under mutation pressure across different cancer types, including a complex bringing together PIK3CA with actomyosin proteins. These papers provide a resource that will be helpful in interpreting cancer genomic data. —VV